# chronic spontaneous urticaria FDA approvals and PDUFA dates

Canonical: https://sec-api.dev/indications/chronic-spontaneous-urticaria

> 6 upcoming FDA catalysts in chronic spontaneous urticaria: Litfulo (ritlecitinib tosylate, PFE) on Dec 2026 to Mar 2027 (topline data readout); Litfulo (ritlecitinib tosylate, PFE) on December 2026 (primary completion); Rhapsido® (remibrutinib, NVS) on May to Aug 2028 (topline data readout); Rhapsido® (remibrutinib, NVS) on May 2028 (primary completion); and 2 more.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, exact day, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| Apr 2025 | [Povofortay (povorcitinib) topline data readout](https://sec-api.dev/pdufa/povorcitinib) | INCY | chronic spontaneous urticaria | completed, positive | "In April 2025, we announced positive topline results from the Phase 2 study evaluating povorcitinib in patients with CSU." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/879169/000087916925000118/incy-20250930.htm)) |
| September 17, 2025 | [Rhapsido® (remibrutinib) primary completion](https://sec-api.dev/pdufa/remibrutinib) | NVS | Chronic Spontaneous Urticaria | completed | "NCT06042478 (Phase 3b Study to Assess the Efficacy, Safety, and Tolerability of Remibrutinib in Comparison to Placebo, With Omalizumab as Active Control, in Adult CSU Patients, Followed by an Open-label 52-week Optional Extension.): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2025-09-17 (ACTUAL); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06042478)) |
| May 29, 2026 | [Evo756, dose 1 primary completion](https://sec-api.dev/pdufa/evo756) | EVMN | Chronic Spontaneous Urticaria | completed | "NCT06873516 (Phase 2b Study of EVO756 in Adults With Moderate to Severe Chronic Spontaneous Urticaria (CSU)): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2026-05-29 (ACTUAL); Lead Sponsor Evommune, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06873516)) |
| August 4, 2026 | [Barzolvolimab primary completion](https://sec-api.dev/pdufa/barzolvolimab) | CLDX | Chronic Spontaneous Urticaria | completed | "NCT06455202 (A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria (CSU)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-08-04 (ACTUAL); Lead Sponsor Celldex Therapeutics." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06455202)) |
| Aug to Nov 2026 | [Barzolvolimab topline data readout](https://sec-api.dev/pdufa/barzolvolimab) | CLDX | Chronic Spontaneous Urticaria | scheduled | "NCT06455202 (A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria (CSU)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-08-04 (ACTUAL); Lead Sponsor Celldex Therapeutics." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06455202)) |
| August 12, 2026 | [Barzolvolimab primary completion](https://sec-api.dev/pdufa/barzolvolimab) | CLDX | Chronic Spontaneous Urticaria | completed | "NCT06445023 (A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-08-12 (ACTUAL); Lead Sponsor Celldex Therapeutics." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06445023)) |
| Aug to Nov 2026 | [Barzolvolimab topline data readout](https://sec-api.dev/pdufa/barzolvolimab) | CLDX | Chronic Spontaneous Urticaria | scheduled | "NCT06445023 (A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-08-12 (ACTUAL); Lead Sponsor Celldex Therapeutics." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06445023)) |
| Nov 2026 to Feb 2027 | [Lou064 (blinded) topline data readout](https://sec-api.dev/pdufa/lou064-blinded) | NVS | Chronic Spontaneous Urticaria | scheduled | "NCT05677451 (24 Weeks Double-blind Randomized Placebo-controlled Trial to Evaluate Efficacy, PK, Safety of LOU064 in Adolescents (12 - <18) With CSU and Inadequate Response to H1-antihistamine Followed by Optional 3 Years Open-label Extension and an Optional 3 Years Safety Long-term Treatment-free Follow-up): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-11-03 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05677451)) |
| November 2026 | [Lou064 (blinded) primary completion](https://sec-api.dev/pdufa/lou064-blinded) | NVS | Chronic Spontaneous Urticaria | scheduled | "NCT05677451 (24 Weeks Double-blind Randomized Placebo-controlled Trial to Evaluate Efficacy, PK, Safety of LOU064 in Adolescents (12 - <18) With CSU and Inadequate Response to H1-antihistamine Followed by Optional 3 Years Open-label Extension and an Optional 3 Years Safety Long-term Treatment-free Follow-up): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-11-03 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05677451)) |
| Dec 2026 to Mar 2027 | [Litfulo (ritlecitinib tosylate) topline data readout](https://sec-api.dev/pdufa/ritlecitinib) | PFE | Chronic Spontaneous Urticaria | scheduled | "NCT07219615 (A Study to Learn About Ritlecitinib for the Potential Treatment of Chronic Spontaneous Urticaria in Adults.): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2026-12-25 (ESTIMATED); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07219615)) |
| December 2026 | [Litfulo (ritlecitinib tosylate) primary completion](https://sec-api.dev/pdufa/ritlecitinib) | PFE | Chronic Spontaneous Urticaria | scheduled | "NCT07219615 (A Study to Learn About Ritlecitinib for the Potential Treatment of Chronic Spontaneous Urticaria in Adults.): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2026-12-25 (ESTIMATED); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07219615)) |
| May to Aug 2028 | [Rhapsido® (remibrutinib) topline data readout](https://sec-api.dev/pdufa/remibrutinib) | NVS | Chronic Spontaneous Urticaria | scheduled | "NCT07816328 (Investigation of a Remibrutinib- and Omalizumab-based Treatment Algorithm in Adult Patients With Chronic Spontaneous Urticaria Inadequately Controlled by H1-antihistamines Within 24 Weeks): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-05-24 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07816328)) |
| May 2028 | [Rhapsido® (remibrutinib) primary completion](https://sec-api.dev/pdufa/remibrutinib) | NVS | Chronic Spontaneous Urticaria | scheduled | "NCT07816328 (Investigation of a Remibrutinib- and Omalizumab-based Treatment Algorithm in Adult Patients With Chronic Spontaneous Urticaria Inadequately Controlled by H1-antihistamines Within 24 Weeks): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-05-24 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07816328)) |
| September 2028 | [Barzolvolimab primary completion](https://sec-api.dev/pdufa/barzolvolimab) | CLDX | Chronic Spontaneous Urticaria | scheduled | "NCT07256392 (Long-term Efficacy and Safety Extension (LTE) Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria): Overall Status ENROLLING_BY_INVITATION; Phase PHASE3; Primary Completion 2028-09 (ESTIMATED); Lead Sponsor Celldex Therapeutics." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07256392)) |
| Sep to Dec 2028 | [Barzolvolimab topline data readout](https://sec-api.dev/pdufa/barzolvolimab) | CLDX | Chronic Spontaneous Urticaria | scheduled | "NCT07256392 (Long-term Efficacy and Safety Extension (LTE) Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria): Overall Status ENROLLING_BY_INVITATION; Phase PHASE3; Primary Completion 2028-09 (ESTIMATED); Lead Sponsor Celldex Therapeutics." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07256392)) |

## Drugs

- [Povofortay (povorcitinib)](https://sec-api.dev/pdufa/povorcitinib) (INCY)
- [Rhapsido® (remibrutinib)](https://sec-api.dev/pdufa/remibrutinib) (NVS)
- [Evo756, dose 1](https://sec-api.dev/pdufa/evo756) (EVMN)
- [Barzolvolimab](https://sec-api.dev/pdufa/barzolvolimab) (CLDX)
- [Lou064 (blinded)](https://sec-api.dev/pdufa/lou064-blinded) (NVS)
- [Litfulo (ritlecitinib tosylate)](https://sec-api.dev/pdufa/ritlecitinib) (PFE)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/indications/chronic-spontaneous-urticaria.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "chronic spontaneous urticaria FDA approvals and PDUFA dates." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/indications/chronic-spontaneous-urticaria

```bibtex
@misc{secapidev_indications_chronic_spontaneous_urticaria_20261116,
  title        = {chronic spontaneous urticaria FDA approvals and PDUFA dates},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/indications/chronic-spontaneous-urticaria}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_indications_chronic_spontaneous_urticaria_20261116","title":"chronic spontaneous urticaria FDA approvals and PDUFA dates","publisher":"sec-api.dev","URL":"https://sec-api.dev/indications/chronic-spontaneous-urticaria","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
